Prediction of Response to the Anti-EGFR Antibody Panitumumab Combined with Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer (TNBC): The Immune and IGFR Pathways

被引：0
|
作者：
Penault-Llorca, F.
Abrial, C.
Douplat, M-M
Privat, M.
Uhrhammer, N.
Desrichard, A.
Bidet, Y.
Radosevic-Robin, N.
Cayre, A.
Aube, C.
Kwiatkowski, F.
Bignon, Y-J
Chollet, P.
Nabholtz, J-M
机构：
[1] Ctr Jean Perrin, Clermont Ferrand, France
[2] Univ Auvergne, EA 4677 ERTICa, Clermont Ferrand, France
来源：
LABORATORY INVESTIGATION | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
254
引用
收藏
页码：63A / 63A
页数：1
相关论文
共 50 条
  • [1] Prediction of Response to the Anti-EGFR Antibody Panitumumab Combined with Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer (TNBC):The Immune and IGFR Pathways
    Penault-Llorca, F.
    Abrial, C.
    Dauplat, M-M
    Privat, M.
    Uhrhammer, N.
    Desrichard, A.
    Bidet, Y.
    Radosevic-Robin, N.
    Cayre, A.
    Aube, C.
    Kwiatkowski, F.
    Bignon, Y-J
    Chollet, P.
    Nabholtz, J-M
    MODERN PATHOLOGY, 2013, 26 : 63A - 63A
  • [2] Response to the anti-EGFR antibody panitumumab combined with standard neoadjuvant chemotherapy in triple negative breast cancer (TNBC): the immune and IGFR pathways
    Penault-Ilorca, Frederique
    Abrial, Catherine
    Dauplat, Marie-Melanie
    Privat, Maud
    Uhrhammer, Nancy
    Desrichard, Alexis
    Bidet, Yannick
    Radosevic-Robin, Nina
    Cayre, Anne
    Aube, Cecile
    Kwiatkowski, Fabrice
    Chalabi, Nassera
    Bignon, Yves-Jean
    Chollet, Philippe
    Nabholtz, Jean-Marc
    CANCER RESEARCH, 2013, 73 (08)
  • [3] Response to the anti-EGFR antibody panitumumab combined with standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC): The in e and IGFR pathways
    Penault-Llorca, Frederique
    Dauplat, Marie-Melanie
    Abrial, Catherine
    Weber, Beatrice E.
    Mouret-Reynier, Marie -Ange
    Gligorov, Joseph
    Tredan, Olivier
    Privet, Maud
    Uhrhammer, Nancy
    Desrichard, Alexis
    Bidet, Yannick
    Radosevic-Robin, Nina
    Cayre, Anne
    Aube, Cecile
    Romero, Pierre Charles
    Kwlatkowski, Fabrics
    Chalabi, Nassera
    Bignon, Yves-Jean
    Chollet, Philippe
    Nabholtz, Jean-Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] HER3, MET and immune pathways play important roles in the resistance of triple negative breast cancer (TNBC) after neoadjuvant anti-EGFR (panitumumab) combined with FEC 100
    Radosevic-Robin, N. Z.
    Abrial, C.
    Dauplat, M. M.
    Kwiatkowski, F.
    Cayre, A.
    Maury, F.
    Roche, M.
    Chalabi, N.
    Mouret-Reynier, M. A.
    Penault-Llorca, F.
    Nabholtz, J. M.
    CANCER RESEARCH, 2013, 73
  • [5] Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
    Nina Radosevic-Robin
    Pier Selenica
    Yingjie Zhu
    Helen H. Won
    Michael F. Berger
    Lorenzo Ferrando
    Emiliano Cocco
    Maud Privat
    Flora Ponelle-Chachuat
    Catherine Abrial
    Jean-Marc Nabholtz
    Frederique Penault-Llorca
    Jorge S. Reis-Filho
    Maurizio Scaltriti
    npj Breast Cancer, 7
  • [6] Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
    Radosevic-Robin, Nina
    Selenica, Pier
    Zhu, Yingjie
    Won, Helen H.
    Berger, Michael F.
    Ferrando, Lorenzo
    Cocco, Emiliano
    Privat, Maud
    Ponelle-Chachuat, Flora
    Abrial, Catherine
    Nabholtz, Jean-Marc
    Penault-Llorca, Frederique
    Reis-Filho, Jorge S.
    Scaltriti, Maurizio
    NPJ BREAST CANCER, 2021, 7 (01)
  • [7] Early prediction of response to Neoadjuvant Immunotherapy in Triple Negative Breast Cancer (TNBC) with DCEMRI
    Rauch, Gaiane
    Guirguis, Mary
    Patel, Miral
    Candelaria, Rosalind
    Mohamed, Rania
    Moseley, Tanya
    Le-Petross, H. T. Carisa
    Leung, Jessica
    Whitman, Gary
    Lane, Deanna
    Scoggins, Marion
    Perez, Frances
    Sun, Jia
    Pashapoor, Sanaz
    Xu, Zhan
    White, Jason
    Wei, Peng
    Reed, Brandy
    Son, Jong Bum
    Hwang, Ken-Pin
    Panthi, Bikash
    Korkut, Anil
    Huo, Lei
    Hunt, Kelly
    Clayborn, Alyson
    Litton, Jennifer
    Valero, Vicente
    Tripathy, Debu
    Yam, Clinton
    Yang, Wei
    Ma, Jingfei
    Adrada, Beatriz
    CANCER RESEARCH, 2024, 84 (09)
  • [8] Immune modulation with humanized anti-EGFR antibody panitumumab in an immunocompetent mouse model for inflammatory breast cancer
    Wang, X.
    Shao, S.
    Pearson, T.
    Cheng, Y.
    Reuben, J. M.
    Tripathy, D.
    Ueno, N. T.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] Clinical and pathological response to neoadjuvant chemotherapy (NCT) in patients with triple negative breast cancer (TNBC)
    Krivorotko, P.
    Zhiltsova, E.
    Gigolaeva, L.
    Emelyanov, A.
    Pesotsky, R.
    Ereschenko, S.
    Levsghenko, V.
    Nikolaev, K.
    Komayachov, A.
    Ivanova, O.
    Tabagua, T.
    Zernov, K.
    Ivanov, V.
    Aseeva, Z.
    Bessonov, A.
    Semiglazov, V.
    BREAST, 2021, 56 : S52 - S52
  • [10] Biomarker identification of residual triple negative breast cancer (TNBC) after standard neoadjuvant chemotherapy (NCT)
    Sohn, Joohyuk
    Liu, Shuyling
    Chen, Huiqin
    Meng, Xiaolong
    Kim-Anh Do
    Mills, Gordon B.
    Hortobagyi, Gabriel N.
    Meric-Bernstam, Funda
    Gonzalez-Angulo, Ana M.
    CANCER RESEARCH, 2012, 72
12345